Corcoran Gavin 4

What Happened
Gavin Corcoran, a director of Verrica Pharmaceuticals (VRCA), was granted a derivative award covering 16,000 shares on 2026-06-05. The award shows an acquisition price of $0.00 (no cash paid) and is recorded as a derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-09.
• Grant: 16,000 shares (derivative), price listed $0.00; total cash paid $0.
• Vesting: The award vests in 12 equal monthly installments beginning July 5, 2026 and will be fully vested by the date of the next annual meeting, subject to continued service as a director.
• Shares owned after transaction: not specified in this Form 4.
• No indication in the filing that any shares were sold or exercised immediately.

Context
This is a typical director compensation grant (derivative award) rather than an outright purchase or sale. Such awards are common for non-employee directors and do not represent an immediate cash investment or liquidation—value is realized only as the award vests and, if applicable, is exercised or converted.